OUR TRACK RECORD
IN LIFE SCIENCE
CORPORATE STRATEGY
Global Fine Chemistry company
We started with 30'000 patents analysed and 400 business cases built to conclude with 10 new product commercial applications in the portfolio, representing 300M€+ in additional revenue - for 1 Business Unit.
We repeated this project framework on 3 BUs.
Mid Size Pharma company
We worked on the Licensing - in & out - strategy to increase internal synergies and increase available resources to diversify the portfolio.
Global Logistic Service Provider
We defined the strategy to build the European Health & Biotech distribution Business Unit, then identified target for infrastructure acquisition to speedup launch readiness.
Global Pharma company
We supported a strategic initiative to identify R&D partners and build a Digital and IoT technologies portfolio, supporting the Pharma portfolio.
GO TO MARKET
Global Diagnostic company
We supported the global launch of clinical decision support AI algorithms, defining and executing the Go To Market Strategy and the Medical Strategy.
Global Pharma company
We lead the Launch Readiness and Launch for an mRNA based COVID-19 vaccine in EMEA, APAC and WHO AMC92 during the pandemic. We coordinated efforts with multiple MoH and Governments, to align CMC timeline and internal infrastructure readiness.
US Biotech company
We defined the European launch strategy, planned the launch readiness - including market access and medical strategy, designed financial and physical flow - for an Oncology small molecule with companion diagnostic.
PROCESS TRANSFORMATION
Global Pharma Company
We identified gaps in Go To Market strategy and execution loop for new products. We automated several workflows with support AI agents to shorten the time to market and increase narrative consistency between Medical and Commercial content.
US Biotech
In the context of establishing a European Headquarter, we designed essential processes from customer invoicing cross-linked with QC, to establishing Customer Service processes and transatlantic physical flows to start manufacturing finished product and deliver to customers.
Global Pharma company
In the context of a new EU regulation, we designed new workflow, built trainings, integrated a new digital solution and rolled out to all European affiliates, with a change management period.
Global Pharma company
We designed a new workflow and process to engage more efficiently with KOLs, removing internal frictions while keeping regulatory guardrails.
M&A, PRIVATE EQUITY
Private Equity Fund
We supported on multiple Life Science related Due Diligence, focusing on IP strength, biology and CMC parameters, scalability, product and portfolio development plan, clinical data evaluation and coherence with financial plan. With these experiences, we automated part of the Due Diligence process with AI in closed, secured environments to maintain confidentiality.
Global Diagnostic company
We supported the integration readiness and execution of a digital solutions portfolio post acquisition. Our project included cross-functional change management, commercial and medical content adaptation, integration in internal global processes and financial monitoring.
Global Pharma company
We supported the acquisition of a Point of Care testing biotech, to complement the Cardiovascular drugs portfolio and innovate on patient treatment adaptation and adherence.
MEA focused Pharma distributors
We carried out the Due Diligence, defined the post-aquisition integration and development strategy and supported on the financing process - for the acquisition of a French distributor with activities in MEA.
GLOBAL SUPPLY CHAIN
Global Pharma company
We lead the Supply Chain plan, setup and operations - cold chain - for the execution of complex contracts between EU, MEA, NGOs and our client. We generated 1B$ revenues in 4 weeks driving this contract execution to its full delivery.
Global Logistic company
We supported our client with a strategy to develop a new business in Europe, dedicated to Biotechnology logistics. We then supported the execution with Internal capabilities development combined with acquisition due diligence of qualified storage infrastructure.
European Warehousing specialist
We defined a growth strategy for our client to (1) enter the market for cold chain biotechnology products and (2) increase its industrial footprint. Our strategy led to a 3x revenues within 3 years
Global Pharma company
Our client had an critical event disrupting its European API supply chain, for which we lead the physical and financial flow adjustment to derive US API to EU fill&finish CMOs, including Regulatory and QC impact.
COMMERCIAL OPERATIONS
Global Pharma company
We supported our client to (1) define the strategy to increase OTC sales in LATAM, (2) review and rebuild all commercial and supply processes, (3) establish a roadmap and clear specifications for the ecommerce platform solution, (4) support the integrator selection and (5) Monitor integration and roll-out.
Biotech company
In a post-acquisition setting, we supported the marketing strategy in APAC to strengthen the client's position in the context of increased competition from China in the region.
Generics and Biosimilar company
We supported our client in developping its marketing and commercial strategy to increase their footprint in France, with a specific oncology portfolio and growing other therapeutic areas.
US Biotech company
Our client wanted to use distributors to sell its main product in Eastern Europe and MEA. We defined key contract elements to ensure commercial incentives, manage costs an ensure relevant services were in place to support with local authorities.